Hyderabad, India-based Aurobindo Pharma's U.S. subsidiary Aurobindo Pharma USA Inc signed a pact to acquire an under-development product and certain related assets from Australia's Advent Pharmaceuticals Pty Ltd., for $12.5 million. The time period for completion of the deal is January 2019. Advent is a specialty pharmaceutical R&D company based in Melbourne,...